泰索帝单周和三周方案二线治疗老年晚期非小细胞肺癌的临床对比研究  

Weekly taxotere comparison with three-weekly taxotere as the second-line chemotherapy for elderly advanced non-small cell lung cancer:A random comparative study

作　　者：包迎红[1] 李骏白[1] 潘峰[1] 周成槎[1] 

机构地区：[1]浙江省温州市第二人民医院化疗科,325000

出　　处：《安徽医学》2008年第2期157-158,共2页Anhui Medical Journal

摘　　要：目的采用化疗药物泰索帝单周和三周方案二线治疗老年晚期非小细胞肺癌,对比观察两组病人的临床疗效和毒副作用。方法经组织学或细胞学确诊的晚期非小细胞肺癌患者82例,随机分为两组,A组:泰索帝75mg/m2IVD1,每3周重复。B组:泰索帝30mg/m2IVD1,D8,D15,每4周重复。化疗3个周期后评价疗效和毒副反应。结果A组有效率(RR)23.1%,B组有效率(RR)16.3%,两组有效率评价无显著性差异(P>0.05)。A组毒副反应明显高于B组,主要为中性粒细胞下降(P<0.005)及粒细胞减少性发热(P<0.01)。结论使用泰索帝每周方案作为老年非小细胞肺癌的二线化疗方案,与标准的三周方案相比,毒副反应降低,而临床疗效没有下降。Objective To observation the efficacy and toxicity using different dosage of weekly and three - week taxotere as second- line chemotherapy for Elderly NSCLC. Methods 82 patients were randomized to receive either taxotere 75 mg/m^2 every 3 weeks（ arm A） or taxotere 30 mg/m^2 weekly for 3 weeks repeated every 4 weeks. Treatment reaction and toxicity were evaluated after three cycles of chemotherapy. Results The reaction rate （RR）was 23. 1% and 16.3% respectively in the two arms. There was no any significant difference between them （ P 〉 0.05 ）. However, there was a significantly higher toxicity, mainly neutropenia and febrile neutropenia in arm A than that in arm B. Conclusion For elderly patients with advanced NSCLC, second -line chemotherapy with weekly taxotere may have a comparable efficacy and better toxcity profile, compared with every -3 - week dosing regime.

关 键 词：老年非小细胞肺癌 泰索帝 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R169.41[医药卫生—临床医学]